allele frequencies ! 5%. These SNPs were segregated into risk and protective SNPs, and each category was collapsed into a single marker, designated by the presence or absence of any rare allele. The presence of any rare allele at a risk SNP was significantly associated with non-DM ESRD (p = 0.001, dominant model). The SNPs with the strongest evidence for association (n = 20) were genotyped in an independent set of 467 non-DM ESRD cases and 279 controls. Although rs10404257 was not associated in this replication sample, when the samples were combined, rs10404257 was modestly associated (p = 0.032, OR = 0.78, CI = 0.63-0.98; dominant model). SNPs were tested for interaction with markers in the APOL1 gene, previously associated with non-DM ESRD in AAs, and rs10404257 was modestly associated (p = 0.0261, additive model). Conclusions: This detailed evaluation of ACTN4 variation revealed limited evidence of association with non-DM ESRD in AAs.
the cell cytoskeleton, contributes to cell structure, and regulates cell motility [2, 3] . Deficiency in the protein in mice has been shown to be directly related to a loss of normal podocyte function [4] . In humans, mutations in ACTN4 have been shown to cause familial focal segmental glomerulosclerosis (FSGS) [1, 5, 6] . Most mutations led to increased actin binding by ACTN4 with subsequent formation of actin aggregates [7] [8] [9] . This form of familial FSGS is an autosomal dominant disorder which is believed to be rare in the general population.
Non-diabetic (non-DM) end-stage renal disease (ESRD) is the second most common cause of advanced kidney disease in African-Americans (AAs) after diabetic nephropathy. AAs are particularly susceptible to FSGS, even when hypertension and socioeconomic factors are considered [10] . Studies in AA families have shown that there is a genetic component to this predisposition to kidney disease [11, 12] .
As rare variants in ACTN4 have been shown to lead to familial forms of FSGS, we hypothesized that similar rare variants in ACTN4 may also lead to increased susceptibility to non-DM ESRD in AAs and thus be more readily detectable. To test this possibility, we sequenced 19 (of 21 total) exons in the ACTN4 gene in AA cases with ESRD and controls.
Methods
Subjects Non-DM ESRD cases self-reporting their race as AA were collected from dialysis clinics in North Carolina, South Carolina, Georgia, Virginia and Tennessee. Patients were classified as having non-DM ESRD if they had hypertension or chronic glomerular disease listed as their primary cause of renal disease. Cases confirmed the onset of high blood pressure prior to development of ESRD, in the absence of other risk factors for kidney disease such as diabetes mellitus. Non-DM ESRD was typically diagnosed in the presence of proteinuria ^ 1.5 g/day, urinalysis ^ 100 mg/dl protein, or spot urine protein:creatinine ratio ^ 1.5 g/g (when data available), with either EKG evidence of left ventricular hypertrophy or presence of hypertensive retinopathy. Chronic glomerulonephritis was diagnosed in those with kidney biopsy evidence or higher levels of proteinuria. Patients with polycystic kidney disease, Alport's syndrome, urologic disease or surgical nephrectomy were excluded. Non-nephropathy controls were self-identified healthy AAs born in North Carolina, age 6 18 years, and denying a personal or family history of kidney disease in first-degree relatives. Each participant provided 40 ml blood for DNA isolation. DNA was isolated from whole blood using an AutoPure LS automated DNA extraction robot (Gentra Systems, Minneapolis, Minn., USA). Recruitment and sample collection procedures were approved by the Institutional Review Board at Wake Forest School of Medicine. All of the subjects in the Wake
Forest case control cohort were tested for relatedness prior to inclusion in the study via identity by descent statistics. Individuals which appear to be first-or second-degree relatives are removed from the sample set.
Subjects were sampled in two groups. Set 1 comprised 296 non-DM ESRD cases and 358 non-nephropathy controls. For the exon sequencing single-nucleotide polymorphism (SNP) discovery stage, 96 cases and 96 controls were randomly selected from set 1 samples. We followed up the initial analysis with replication in set 2 samples, which comprised 467 non-DM ESRD cases and 279 non-nephropathy controls. Finally, we performed a combined association analysis of all the samples, 763 non-DM ESRD cases and 637 non-nephropathy controls.
Sequencing
We sequenced 19 exons, 2,800 bases of the promoter region and 392 bases of the 3 untranslated region in the ACTN4 gene in 96 AA non-DM ESRD cases and 96 AA non-nephropathy controls. PCR primers were designed to amplify regions approximately 500 bases at a time, and nested to provide complete coverage of the promoter region and exons. Primer sequences are available upon request. Each 500-base region was PCR amplified and the product was purified. DNA sequencing was performed using Big Dye Ready Reaction Mix (Applied Biosystems, Foster City, Calif., USA) on an ABI3730xl sequencer (Applied Biosystems). Sequence data were visualized using Sequencher Software v4.6 (GeneCodes Corporation, Ann Arbor, Mich., USA). Exons 20 and 21 and a portion of the 3 untranslated region of the ACTN4 gene could not be sequenced due to a region on chromosome 4 with a highly similar sequence.
SNP Genotyping
Forty-one of the 67 SNPs were genotyped using the Sequenom MassARRAY genotyping system (Sequenom, San Diego, Calif., USA). Genotyping primers were designed using the MassARRAY Assay Design 3.4 Software (Sequenom); sequences will be provided upon request. Twenty-one SNPs could not be designed using the MassARRAY system due to close proximity of other SNPs or other assay design issues. These SNPs were sequenced using the primer sequences for the initial screen as described above. The 21 SNPs for sequencing were chosen based on their location with the intent to maximize the number of SNPs that could be captured using the least number of primers. Five SNPs were not genotyped by Sequenom or sequencing (see SNPs in bold in table 2). Four of these SNPs (C-2752T, C58279T, C61663G, and G76310A) were extremely rare, with only 1 or 2 individuals identified, and we elected not to pursue them. The fifth SNP, G61675T, was in high linkage disequilibrium with another SNP which was genotyped, G61672A, and was not genotyped separately. To calculate percentage of African ancestry, 70 ancestry informative markers were genotyped on all cases and controls. Percentage of African ancestry was calculated using the computer program FRAPPE as described previously [13] .
Statistical Analysis
Age, BMI and percentage of African ancestry for the non-DM ESRD cases and healthy controls were compared using an unpaired t test or a Mann-Whitney rank sum test where appropriate (SigmaStat 3.5, SYSTAT Software, San Jose, Calif., USA). Departures from Hardy-Weinberg equilibrium (HWE) were tested for each SNP us-ing 2 goodness-of-fit statistics in our association analysis program SNPGWA [14] . Tests for association included the overall 2-degree of freedom genotype test of association and three a priori genetic models (i.e. dominant, additive, and recessive).
To test for association at rare alleles (minor allele frequency, MAF ! 0.05), we collapsed these variants into a single marker using the following technique. For each individual, the presence of any rare allele (at any SNP), the individual was coded with the genotype '1 2'. Individuals with no rare alleles at any SNP were coded with the genotype '2 2'. Therefore, all samples were coded with either a 1 2 or 2 2 genotype. This single marker was then tested for association with case status using SNPGWA as described above. This technique was used to test for association at SNPs in the promoter region only and the promoter region combined with sequenced exons. We collapsed 47 of the 62 SNPs genotyped in set 1 into a single marker. In addition, we also collapsed just the 17 rare SNPs that were located in the promoter region (which were also included in the 47 SNPs).
For the genotyping of the set 2 DNA samples, 20 SNPs were selected from the list of 62 SNPs genotyped in set 1 ( table 3 ). The SNPs were ranked by the 2-degree of freedom p value and were combined into the largest possible single assay in succession. If an SNP did not plex with the assay, the next ranked SNP would be chosen for assay design. As a result, there are SNPs included in the assay that were not necessarily the most associated SNP by rank ( table 4 ) .
We tested the 20 SNPs that were genotyped on both sets of samples as well as the collapsed rare alleles for interaction with risk at the apolipoprotein L1 (APOL1) risk variants. The G1 and G2 risk variants (as described by Genovese et al. [15] ) were genotyped on all samples using the Sequenom MassArray system (Sequenom). Case only and case control tests of association were performed for gene-gene interaction between the 20 SNPs and the APOL1 G1 and G2 risk haplotypes. This test models APOL1 risk as the response for all individuals with recessive haplotypes at either G1 or G2 or heterozygosity at both G1 and G2. Interaction analyses were adjusted for age, gender and percentage of African ancestry. Table 1 summarizes characteristics of the study samples. Two sample sets were evaluated. Set 1 consisted of 296 AAs with non-DM ESRD and 358 non-nephropathy controls in which the non-DM ESRD cases were older, had lower BMI and were slightly higher in percentage of African ancestry ( table 1 ) than controls. There was no significant difference in gender proportions between cases and controls in this group. The replication sample, designated as set 2, consisted of 467 AAs with non-DM ESRD and 279 non-nephropathy controls. Similar to set 1, the set 2 cases were older, had fewer females, lower BMI and higher percentage of African ancestry than the set 2 controls. These trends remained consistent when the samples were combined in a final set of 763 cases and 637 controls.
Results
The variants identified by sequencing the 384 chromosomes in 96 non-DM ESRD cases and 96 non-nephropathy controls are listed in table 2 . Known variants are identified by their dbSNP ID, and novel variants are identified by position relative to the first nucleotide of exon 1. We identified 67 variants in the ACTN4 gene, 51 of which were novel. Twenty-one SNPs were in the promoter region, 12 were coding SNPs, 33 were intronic and 1 SNP was in the 3 untranslated region. Of the 12 coding SNPs, only C58409T in exon 5 was non-synonymous, resulting in a proline to leucine amino acid change. The majority of the SNPs (n = 47) were rare, with MAFs ! 0.05 in the control samples. One SNP, rs2112649, had three alleles in our samples. As the A allele has not been previously reported for this SNP, we sequenced this individual in the forward and reverse directions to confirm the presence of the third allele. A single case individual possessed an A allele at this locus, whereas all other individuals tested had a G or C. For association tests, which require 2 alleles, we coded the A allele as unknown. Sixty-two SNPs were genotyped in set 1 cases and controls. As set 1 samples comprised the 96 cases and controls that made up the SNP discovery set, we compared the genotypes derived from sequencing with those derived from Sequenom genotyping, and all genotypes were 100% concordant. Association analysis revealed significance at rs10404257 (p ! 0.0001, additive model), A-98C (p = 0.001, dominant model), and rs2112649 (p = 0.010, additive model; table 3 ). Another SNP, C62517T, was significantly associated; however, this SNP deviated significantly from HWE proportions in all groups of control samples. This SNP is a coding, synonymous variant and was eliminated from further analysis. Both rs10404257 and rs2112649 remained significantly associated after adjustment for age, BMI, gender and African ancestry (p = 0.004, odds ratio, OR = 0.60, confidence interval, CI = 0.43-0.85, dominant model; p = 0.026, OR = 1.31, CI = 1.03-1.67, additive model).
A number of SNPs were rare (MAF ! 0.05), and our current association tests are not powerful at such low frequencies. To overcome this limitation, we collapsed rare alleles together and tested for association. Rare SNPs in the promoter region only (17 SNPs) and throughout the entire gene including the promoter (47 SNPs) were collapsed into a single marker where the presence of a rare allele was coded as '1 2' and the absence of a rare allele was coded as '2 2' (see 'Methods' for complete details). A total of 251 individuals had at least 1 rare allele, whereas 404 individuals had only the common alleles. Neither the rare SNPs in the promoter region (p = 0.981), nor those throughout the entire gene (p = 0.166) were associated with non-DM ESRD in the set 1 samples.
One major drawback to this method of collapsing the rare alleles is that directionality of the alleles (i.e. risk vs. protective) is not taken into consideration. To overcome Pos ition is shown relative to the Hg19 assembly of the human genome (column 3) and the first nucleotide of exon 1 (column 4). Samples in bold were only genotyped on 96 cases and 96 controls from set 1, whereas the remaining SNPs were identified by sequencing and subsequently genotyped in the entire set 1 samples, 296 non-DM ESRD cases and 358 non-nephropathy controls. Total alleles shows the number of copies of the minor allele present in cases and controls. InterSNP linkage disequilibrium is shown by r 2 for each SNP and the SNP immediately following. Association is shown for the 2-degree of freedom test (2DF) followed by the three genetic models: dominant (Dom), additive (Add), and recessive (Rec). this limitation, we have segregated the SNPs into 'protective' and 'risk' categories based on their allele frequencies in cases and controls. Sixteen SNPs were categorized as protective, whereas 24 SNPs were categorized as risk. The two categories were collapsed and tested for association as described above. The SNPs collapsed into the protective category were not significantly associated with ESRD, p = 0.260. However, the SNPs collapsed into the risk category were significantly associated with ESRD, p = 0.006, twodegree of freedom test, and 0.001, dominant model. Twenty of the SNPs from the set 1 analysis which had the greatest evidence of association were genotyped in the set 2 samples, 467 cases and 279 controls ( table 4 ) . A single SNP, A-98C, was associated (p = 0.0002, OR = 0.23, CI = 0.08-0.64, additive model). When the two sample sets were combined, one SNP rs10404257 was modestly associated (p = 0.032, OR = 0.78, CI = 0.63-0.98, dominant model). Adjustment for age, gender, BMI and African ancestry did not change the p value, (p = 0.033). As rs10404257 was not associated in set 2 samples, the significant p value in the combined sample set is driven by association in set 1. This result does not meet evidence of association accounting for multiple comparisons. The other modestly significant SNP, rs2112649, failed genotyping in set 2 samples.
Recently, two markers on APOL1 were shown to significantly contribute to risk of ESRD in AAs [15] . These risk variants have been designated as G1 (a haplotype consisting of rs73885319 and rs60910145) and G2 (rs71785313). Despite the highly significant contribution to risk, second hits (gene-gene or gene-environment interactions) are required for initiation of renal disease. We hypothesize that there are other genetic markers that may interact with APOL1 G1 and G2 risk variants. Therefore, we tested rs10404257 and the collapsed rare alleles for interaction with APOL1 risk alleles G1 and G2 [15] . There was no evidence of interaction with APOL1 risk alleles for the marker derived from collapsed rare alleles (p = 0.16, recessive model); however, rs10404257 was modestly associated (p = 0.026, additive model).
Discussion
We sequenced 19 of the 21 exons in the ACTN4 gene, and identified a total of 67 variants in 96 AA non-DM ESRD cases and 96 AA non-nephropathy controls. Although initial genotyping of 62 markers revealed some evidence of association in set 1 samples, when set 2 samples (with a combined total of 763 cases and 637 controls) were included, these SNPs were no longer associated, leading us to conclude that they are the result of spurious association.
The majority of the identified variants are rare (MAF ! 0.05), as would be expected from exon sequencing. Tests for association in these rare variants are low in power and largely limited to variants of large effect. Given the impact of other ACTN4 mutations, this remained a reasonable possibility. In order to analyze these variants for association, we collapsed the rare variants into a single variant. We were able to compare the presence or absence of rare variants in cases and controls using this method. We did not find any association when the rare variants were collapsed; although once samples were segregated based of directionality (risk vs. protective), the variants which were categorized as risk were significantly associated with increased risk of ESRD. While it appears as though the presence of rare 'risk' alleles contributes to ESRD, it should be noted that the two individuals who possessed the largest numbers of rare risk alleles (one individual had 7 risk alleles, and one had 6) were both non-nephropathy controls. Clearly, the role of these rare variants is more complicated than the initial analysis indicates. We propose that additional investigation using a larger sample size is warranted, with some additional consideration for the potential functional roles of these variants.
The absence of variants in the promoter and exons of the ACTN4 gene associated with non-DM ESRD in AAs is surprising but not entirely unlikely. This gene is ubiquitously expressed, and is important for maintaining cell structure and motility. It is possible that defects in this gene result in significant alterations of function that would be catastrophic and unable to be retained across generations. Indeed, the familial FSGS cases that have been identified are isolated in individual families, and afflicted members suffer a range of kidney diseases at young ages. We have scanned the available literature for previous examples of association at the variants we have identified; however, none of the variants we have noted are described as being associated with FSGS previously. This outcome is not entirely unexpected considering that little to no work has been done in AA samples and highlights the need for continuing research on this population.
Through the genotyping of the promoter region and 19 exons of ACTN4 , we have identified a total of 62 variants, most of which are in the non-coding regions of the gene. Despite the large number of variants identified, few were common, and none were associated with non-DM ESRD in AA cases and controls. Collapsing of the risk variants into a single marker resulted in significant asso-ciation, which should be followed up in future studies. Despite the role of ACTN4 in familial FSGS and the important function of the ACTN4 gene, variants in this gene do not appear to contribute significantly to non-DM ESRD in AAs.
